Newsmakers

Phunware (NASDAQ: PHUN) Releases New Blockchain-Enabled Data Exchange Capabilities

Delivers New Feature Sets for Political and Advocacy Solutions within Phunware’s Multiscreen-as-a-Service (MaaS) Platform Phunware, Inc. (NASDAQ: PHUN) (the “Company”), a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands worldwide, […]

Healthcare

Zylo and Hoth Therapeutics (NASDAQ: HOTH) Forge Partnership to Develop Endocannabinoid-Based Drug to Treat Lupus

Greenville, SC, Aug. 22, 2019 — Zylo Therapeutics, dedicated to bringing innovative topical technologies to multiple facets of medicine, has entered into a definitive partnership agreement with Hoth Therapeutics (NASDAQ: HOTH) to develop a new treatment for […]

Newsmakers

Medicine Man Technologies (OTC: MDCL) to Acquire One of Colorado’s Top Award-Winning and Best-Selling Edible Producers

– Strengthens Company’s portfolio with the manufacturers of leading high-quality, crafted cannabis edibles and extracts – Continues to establish itself as a vertically integrated operator with the latest acquisition announcement – Gains access in close […]

Newsmakers

CytoDyn (OTC: CYDY) Provides Update on Dose Escalating Trial with Leronlimab for HIV Monotherapy for a Potential Pivotal Trial

VANCOUVER, Washington, Aug. 14, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today an […]

Newsmakers

NexTech AR (OTC: NEXCF) Signs eCommerce Deal with Cannabis Air Purification Company Alpine Innovative Research Inc.

NEW YORK and TORONTO, Aug. 13, 2019  — NexTech AR Solutions (the “Company” or “NexTech”) (OTCQB:NEXCF) (CSE:NTAR) (FSE:N29) is pleased to announce that it has entered into an agreement with Alpine Innovative Research Inc., a leading […]

Healthcare

CytoDyn (OTC: CYDY) Files a Phase 2 Protocol with the FDA for Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer

VANCOUVER, Washington, Aug. 08, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the […]

Healthcare

Patient Treated with Leronlimab (PRO 140) for Metastatic Triple-Negative Breast Cancer under Emergency IND, Launching CytoDyn (OTC: CYDY) into Oncology

VANCOUVER, Washington, Aug. 06, 2019 – CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the […]